secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-04-21T23:59:59+00:00
Accession:  0001831283-23-000067
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

China NMPA accepts with priority review LianBio's NDA for mavacamten in oHCM
----------------------------------------------------------------------------

- NMPA accepted NDA for mavacamten for symptomatic obstructive HCM in adults; priority review granted.
- NDA based on global Phase 3 EXPLORER-HCM trial and LianBio's Phase 1 PK study in Chinese volunteers.
- Blinded preliminary safety data from ongoing Phase 3 EXPLORER-CN trial supported early filing; topline results expected mid-2023.
- CEO states this is a pivotal moment as LianBio prepares to become a commercial-stage company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000067/0001831283-23-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000067/lian-20230421.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer